A 60-year-old man with rheumatoid arthritis will be started on a non-steroidal anti-inflammatory drug to suppress joint inflammation. Published pharmacokinetic data for this drug include Bioavailability (F): 1.0 (100%) Plasma half-life (t1/2): 0.5 h Volume of distribution (Vd): 45 L For this drug, it is important to maintain an average steady-state concentration 2.0 mcg/mL in order to ensure adequate and continued anti-inflammatory activity. The drug will be given (taken) every 4 h. What dose will be needed to obtain an average steady-state drug concentration of 2.0 mcg/mL?